HRP20020429B8 - Polimorfni oblik atorvastatin kalcija - Google Patents

Polimorfni oblik atorvastatin kalcija

Info

Publication number
HRP20020429B8
HRP20020429B8 HR20020429A HRP20020429A HRP20020429B8 HR P20020429 B8 HRP20020429 B8 HR P20020429B8 HR 20020429 A HR20020429 A HR 20020429A HR P20020429 A HRP20020429 A HR P20020429A HR P20020429 B8 HRP20020429 B8 HR P20020429B8
Authority
HR
Croatia
Prior art keywords
atorvastatin calcium
polymorph form
form atorvastatin
theta
peak
Prior art date
Application number
HR20020429A
Other languages
English (en)
Croatian (hr)
Inventor
Ayalon Ari
Levinger Michal
Roytblat Sofia
Lifshitz Revital
Niddam Valerie
Aronhime Judith
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HRP20020429A2 publication Critical patent/HRP20020429A2/xx
Publication of HRP20020429B1 publication Critical patent/HRP20020429B1/xx
Publication of HRP20020429B8 publication Critical patent/HRP20020429B8/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
HR20020429A 1999-11-17 2000-11-16 Polimorfni oblik atorvastatin kalcija HRP20020429B8 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16615399P 1999-11-17 1999-11-17
PCT/US2000/031555 WO2001036384A1 (en) 1999-11-17 2000-11-16 Polymorphic form of atorvastatin calcium

Publications (3)

Publication Number Publication Date
HRP20020429A2 HRP20020429A2 (en) 2004-04-30
HRP20020429B1 HRP20020429B1 (en) 2006-05-31
HRP20020429B8 true HRP20020429B8 (hr) 2007-03-31

Family

ID=22602039

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020429A HRP20020429B8 (hr) 1999-11-17 2000-11-16 Polimorfni oblik atorvastatin kalcija

Country Status (20)

Country Link
EP (3) EP1235799B1 (cs)
JP (2) JP2003514798A (cs)
KR (1) KR20020063190A (cs)
CN (1) CN1423634A (cs)
AT (2) ATE478665T1 (cs)
AU (1) AU783002B2 (cs)
CA (1) CA2392096C (cs)
CZ (1) CZ20021642A3 (cs)
DE (2) DE60044884D1 (cs)
ES (2) ES2234699T3 (cs)
HR (1) HRP20020429B8 (cs)
HU (1) HUP0203257A3 (cs)
IL (2) IL149681A0 (cs)
PL (1) PL355805A1 (cs)
PT (2) PT1535613E (cs)
SI (2) SI1235799T1 (cs)
SK (1) SK286789B6 (cs)
WO (1) WO2001036384A1 (cs)
YU (1) YU35802A (cs)
ZA (1) ZA200203755B (cs)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
JP2004513956A (ja) 2000-11-03 2004-05-13 テバ　ファーマシューティカル　インダストリーズ　リミティド アトルバスタチンヘミカルシウムｖｉｉ型
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) * 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
WO2003004470A1 (en) * 2001-06-29 2003-01-16 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
MXPA04000889A (es) 2001-07-30 2004-06-03 Reddys Lab Ltd Dr Formas cristalinas vi y vii de atorvastatina calcica.
US7074818B2 (en) 2001-07-30 2006-07-11 Dr. Reddy's Laboratories Limited Crystalline forms VI and VII of Atorvastatin calcium
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
WO2003070702A1 (en) * 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
US7122681B2 (en) 2002-02-19 2006-10-17 Teva Pharmaceutical Industries, Ltd. Desolvation process for the production of atorvastatin hemi-calcium essentially free of bound organic solvent
JP2005532362A (ja) * 2002-06-13 2005-10-27 ノバルティス アクチエンゲゼルシャフト インドール誘導スタチンのカルシウム塩
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
WO2004050618A2 (en) * 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
BRPI0510713A (pt) * 2004-05-05 2007-11-20 Pfizer Prod Inc formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
BRPI0513422A (pt) * 2004-07-20 2008-05-06 Warner Lambert Co formas de sais cálcio do ácido (r-(r*))-2-(4- fluorfenil)-(beta), (sigma)-diidróxi-5-(1-metiletil) -3-fenil-4-((fenilamino) carbonil)-1h-pirrol-1-heptanóico (2:1)
TWI321132B (en) 2004-09-28 2010-03-01 Teva Pharma Process for preparing forms of atorvastatin calcium substantially free of impurities
ES2272206T1 (es) 2004-10-18 2007-05-01 Teva Pharmaceutical Industries Ltd. Procedimiento para la preparacion de la atorvastatina hemicalcica amorfa por disolucion de la sal en un disolvente organico que es una mezcla de un alcohol, y una cetona y/o un ester y eliminacion del disolvente.
NZ554541A (en) 2004-10-28 2011-01-28 Warner Lambert Co Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
CA2588216A1 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
CA2499047A1 (en) 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
CA2619040C (en) 2005-08-15 2015-02-10 Arrow International Limited Crystalline and amorphous sodium atorvastatin
CA2619486C (en) 2005-08-15 2015-05-12 Arrow International Limited Crystalline and amorphous sodium atorvastatin
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
EP1808162A1 (en) 2005-11-21 2007-07-18 Teva Pharmaceutical Industries Ltd. Atorvastatin pharmaceutical formulation
PT1957452E (pt) 2005-11-21 2010-05-25 Warner Lambert Co Novas formas de ácido [r-(r*,r*)]-2-(4-fluorofenil)-b,b--di-hidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)-carbonil]-1h-pirrole-1-heptanóico magnésico
EP1923057A1 (en) 2005-11-21 2008-05-21 Teva Pharmaceutical Industries Ltd Atorvastatin pharmaceutical formulation
CA2633268A1 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2007096903A2 (en) * 2006-02-22 2007-08-30 Matrix Laboratories Ltd New crystalline form of atorvastatin hemi-calcium
WO2008108572A1 (en) * 2007-03-02 2008-09-12 Dong-A Pharm. Co., Ltd. Novel crystal forms of pyrrolylheptanoic acid derivatives
EP2170841A1 (en) 2007-06-29 2010-04-07 Merck Generics (UK) Limited Process for introduction of hydroxyethoxy side chain in bosentan
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
CA2703230A1 (en) 2007-10-24 2009-04-30 Generics [Uk] Limited Novel crystalline forms
JP5683276B2 (ja) 2008-02-08 2015-03-11 ジェネリクス・［ユーケー］・リミテッド ボセンタンの製造方法
WO2010061210A1 (en) 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
EP2327682A1 (en) * 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) * 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN102249978A (zh) * 2011-06-09 2011-11-23 浙江金立源药业有限公司 阿托伐他汀钙的ky晶型及制备方法
CN103483238B (zh) * 2013-08-20 2014-12-31 蚌埠丰原医药科技发展有限公司 阿托伐他汀钙三水合物的制备方法
US9701636B2 (en) 2013-11-15 2017-07-11 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN104945300B (zh) * 2015-06-17 2017-05-10 北京嘉林药业股份有限公司 一种ⅰ型阿托伐他汀钙的纯化方法
CN105085362B (zh) * 2015-09-18 2018-01-05 浙江海森药业有限公司 高纯度结晶型阿托伐他汀钙的制备方法
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
SG45369A1 (en) * 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
IL128862A (en) * 1995-07-17 2007-12-03 Warner Lambert Co [R - (R * R *)] - 2 - (4 - fluorophenyl) - ß, d - dihydroxy - 5 - (1 - methyl - ethyl) 3 - phenyl - 4 - [(phenamino) carbonyl)] - 1H - Pyrol - 1 - Patenoic acid Hydrogen salt Hydrogen crystalline (Atorostatin) Crystalline hydrate
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)

Also Published As

Publication number Publication date
EP1535613A2 (en) 2005-06-01
SK286789B6 (sk) 2009-05-07
CA2392096C (en) 2008-07-15
DE60044884D1 (de) 2010-10-07
ES2349364T3 (es) 2010-12-30
EP1535613B1 (en) 2010-08-25
EP1235799B1 (en) 2005-02-09
JP2009102439A (ja) 2009-05-14
EP1235799A1 (en) 2002-09-04
JP2003514798A (ja) 2003-04-22
PT1535613E (pt) 2010-10-04
AU1617301A (en) 2001-05-30
SI1535613T1 (sl) 2010-12-31
EP2206497A1 (en) 2010-07-14
AU783002B2 (en) 2005-09-15
ZA200203755B (en) 2004-05-26
SI1235799T1 (en) 2005-06-30
DE60018100T2 (de) 2005-09-15
ATE288893T1 (de) 2005-02-15
ATE478665T1 (de) 2010-09-15
EP1535613A3 (en) 2005-08-31
WO2001036384A1 (en) 2001-05-25
PT1235799E (pt) 2005-05-31
YU35802A (sh) 2005-07-19
HRP20020429A2 (en) 2004-04-30
EP1235799A4 (en) 2003-05-28
PL355805A1 (en) 2004-05-17
CZ20021642A3 (cs) 2003-05-14
IL149681A0 (en) 2002-11-10
KR20020063190A (ko) 2002-08-01
HRP20020429B1 (en) 2006-05-31
DE60018100D1 (en) 2005-03-17
HUP0203257A2 (hu) 2003-01-28
CA2392096A1 (en) 2001-05-25
HUP0203257A3 (en) 2003-05-28
ES2234699T3 (es) 2005-07-01
IL149681A (en) 2007-06-17
CN1423634A (zh) 2003-06-11
SK6742002A3 (en) 2003-05-02

Similar Documents

Publication Publication Date Title
HRP20020429B8 (hr) Polimorfni oblik atorvastatin kalcija
NO20032758D0 (no) Krystallinske former av Atorvastatin
ID24962A (id) Turunan-turunan sulfonamida sebagai bakal obat dari
NO20023582L (no) Asymmetrisk syntese av pregabalin
DE69432937D1 (de) Chirurgisches laparoskopisches Instrument
MY152846A (en) New salts of valsartan
NO20030559D0 (no) Fremgangsmåte for produksjon av papir
MA27349A1 (fr) Composition cristalline renfermant de l'escitalopram.
EP1534695A4 (en) tyrosine kinase inhibitors
NO20023549L (no) Fremgangsmåte for rensing av 1,2-dikloretan
ATE231521T1 (de) Kristalline formen von eto2c-ch2-(r)cgl-aze-pab- oh
NO20040390L (no) Krystallinske former VI og VII av atorvastatinkalsium.
NO20024538D0 (no) Overföring av kontrollinformasjon
ATE240934T1 (de) Wasserhaltiges, kristallines calcium-salz der simvastatin dihydroxy offene säure
NO20035380D0 (no) Fremgangsmåte for dannelse av m degree nster
NO20042667L (no) Fremgangsmate for fremstilling av escitalopram
NO20023837D0 (no) Modulering av bendannelse
HRP20030853B1 (en) Crystalline form of omeprazole
DE69919049D1 (de) Herstellung von gefällten Kalziumkarbonatenthaltenden Produkten
DK0768304T3 (da) Hidtil ukendte sulfonamider
AU2002354114A1 (en) Bisimide compound, acid generator and resist composition each containing the same, and method of forming pattern from the composition
TR28116A (tr) Sapma dalga bicimi düzeltme devresinin zamanlanmasi.
ATE356105T1 (de) Wiedergewinnung von nitroxyl-enthaltenden strömen bei niedriger temperatur
DE69929315D1 (de) Kristalline formen von 1s-ä1alpha(2s*,3r*),9alphaü-6,10-dioxo-n- (2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-ää(1-isochinolyl)carbonylü- aminoüoctahydro-6h-piridazinoä1,2-aüä1,2üdiazepin-1-carboxyamid
EP1496898A4 (en) Tyrosine kinase inhibitor

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
B8IS Corrected front page of an hr-b document
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081115

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20091117